All articles by Alex Watt

Keytruda and Opdivo: a decade review

PD-1 inhibitors have become a paramount achievement in the oncology space and have revolutionised cancer treatment over the last decade.…
Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

In December 2023, Vertex (US) and CRISPR Therapeutics’s (Switzerland and US) Casgevy (exagamglogene autotemcel) was approved in the US for…
Ukraine: a market access review over two years of war

Since the Russian invasion of Ukraine in early 2022, the Ukrainian budget has prioritised national security and defence. However, other…
The privileged status of orphan medicines in Germany

In Germany, new measures have come into effect as part of the GKV-FinStG Act in 2022 that put into question…
Defining the HTA landscape for France and Germany: 2019–2023

Health technology assessments (HTA), defined by the World Health Organization (WHO) as “the systematic evaluation of properties, effects and/or impacts…

EU access to oncology medicines lags behind in the Netherlands

Recently, a study published in the National Library of Medicine compared market access trends in Belgium, France, Hungary, Italy, Switzerland,…
Insights from ISPOR Europe 2023: Copenhagen

Recently back from the beautiful city of Copenhagen, it was an honour to see some of the brightest minds in…
Semaglutide: a price and HTA comparison between US and top European markets

The US is known for having higher list prices for drugs than other high-income countries. But these higher prices have…
HTA outcomes in top European markets grow at a rate of 27% while focusing on oncology

Health technology assessments (HTA) are a formalized process for evaluating the value of a given health intervention. The outcomes of…
Economic unrest results in an average pharmaceutical price trend of 1,123% in Lebanon

Lebanon’s ongoing economic crisis and changes in pricing strategies have caused monumental price hikes that impact market access. In Lebanon,…